Patents by Inventor Trinadha Rao Chitturi
Trinadha Rao Chitturi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240066014Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 11, 2023Publication date: February 29, 2024Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Krishnaji DAMLE, Sanjay Nandlalji MANDHANE, Manoj Atmaramji UPADHYA, Sameer Vishwanath MEHETRE, Gajanan Uttamrao CHIDREWAR, Prabal SENGUPTA, Trinadha Rao CHITTURI
-
Patent number: 11813252Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 18, 2022Date of Patent: November 14, 2023Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Krishnaji Damle, Sanjay Nandlalji Mandhane, Manoj Atmaramji Upadhya, Sameer Vishwanath Mehetre, Gajanan Uttamrao Chidrewar, Prabal Sengupta, Trinadha Rao Chitturi
-
Patent number: 11583522Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 1, 2020Date of Patent: February 21, 2023Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Krishnaji Damle, Sanjay Nandlalji Mandhane, Manoj Atmaramji Upadhya, Sameer Vishwanath Mehetre, Gajanan Uttamrao Chidrewar, Prabal Sengupta, Trinadha Rao Chitturi
-
Patent number: 11465990Abstract: The present invention provides novel heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/degraders and process for their preparation.Type: GrantFiled: October 28, 2020Date of Patent: October 11, 2022Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Ranjan Kumar Pal, Amit Pravinbhai Sedani, Kaushikkumar Dhanjibhai Prajapati, Dijixa Pinakin Rana, Sandeep Pankajbhai Pathak, Japan Nitinkumar Desai, Jayraj Dilipbhai Aradhye, Bhavesh Mohanbhai Panchal, Indraneel Ghosh, Trinadha Rao Chitturi
-
Publication number: 20220273632Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 18, 2022Publication date: September 1, 2022Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Krishnaji DAMLE, Sanjay Nandlalji MANDHANE, Manoj Atmaramji UPADHYA, Sameer Vishwanath MEHETRE, Gajanan Uttamrao CHIDREWAR, Prabal SENGUPTA, Trinadha Rao CHITTURI
-
Publication number: 20220242874Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof (wherein X, Y, Z and n are defined herein). These compounds are useful in the treatment of diseases mediated by topoisomerase I enzyme such as cancers. Also provided are processes for the preparation of compounds of Formula I. The compounds are more water soluble, stable in buffer solution at various pH, and exhibit better anti-tumor activity and rapid release of SN-38 in tumor microenvironments.Type: ApplicationFiled: July 13, 2020Publication date: August 4, 2022Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITEDInventors: Jiten Ranchhodbhai PATEL, Gopalkumar Chimanlal PATEL, Omkar Prakash GORE, Prabal SENGUPTA, Trinadha Rao CHITTURI
-
Publication number: 20220127266Abstract: The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.Type: ApplicationFiled: January 4, 2022Publication date: April 28, 2022Inventors: Gaurav Sanjivkumar Sheth, Sabbirhusen Yusufbhai Chimanwala, Tushar Mukund Jarag, Aishwarya Hampiholi, Saikat Maity, Prabal Sengupta, Gulamnizami Abdulsattar Qureshi, Umesh Vishnu Chaudhari, Raj Gopal Venkat, V.S.N Murty Kadiyala, Sairam VVM Kalapatapu, Vaibhav Jain, Trinadha Rao Chitturi
-
Patent number: 11225480Abstract: The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans. The novel compounds have a structure according to Formula I or a pharmaceutically acceptable salt, stereoisomer or deuterated analog thereof, wherein X, R1, R2 and Y are as described herein.Type: GrantFiled: October 16, 2020Date of Patent: January 18, 2022Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTDInventors: Gaurav Sanjivkumar Sheth, Sabbirhusen Yusufbhai Chimanwala, Tushar Mukund Jarag, Aishwarya Hampiholi, Saikat Maity, Prabal Sengupta, Gulamnizami Abdulsattar Qureshi, Umesh Vishnu Chaudhari, Raj Gopal Venkat, V. S. N. Murty Kadiyala, Sairam V V M Kalapatapu, Vaibhav Jain, Trinadha Rao Chitturi
-
Publication number: 20210261534Abstract: A selective estrogen receptor degrader (SERD), a compound 3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, and its S enantiomer, (2S)-3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, or pharmaceutically acceptable salts thereof. Also provided are processes for their preparation. Also provided for is the use of these compounds for the treatment of diseases which are related to modulation of estrogen receptors, such as ER-positive breast cancer.Type: ApplicationFiled: May 5, 2021Publication date: August 26, 2021Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITEDInventors: Ranjan Kumar PAL, Biswajit SAMANTA, Jayraj Dilipbhai ARADHYE, Sandeep Pankajkumar PATHAK, Kaushik Dhanjibhai PRAJAPATI, Bhavesh Mohanbhai PANCHAL, Trinadha Rao CHITTURI
-
Patent number: 11014915Abstract: A selective estrogen receptor degrader (SERD), a compound 3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, and its S enantiomer, (2S)-3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, or pharmaceutically acceptable salts thereof. Also provided are processes for their preparation. Also provided for is the use of these compounds for the treatment of diseases which are related to modulation of estrogen receptors, such as ER-positive breast cancer.Type: GrantFiled: July 22, 2020Date of Patent: May 25, 2021Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITEDInventors: Rajan Kumar Pal, Biswajit Samanta, Jayraj Dilipbhai Aradhye, Sandeep Pankajkumar Pathak, Kaushik Dhanjibhai Prajapati, Bhavesh Mohanbhai Panchal, Trinadha Rao Chitturi
-
Publication number: 20210115038Abstract: The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.Type: ApplicationFiled: October 16, 2020Publication date: April 22, 2021Inventors: Gaurav Sanjivkumar Sheth, Sabbirhusen Yusufbhai Chimanwala, Tushar Mukund Jarag, Aishwarya Hampiholi, Saikat Maity, Prabal Sengupta, Gulamnizami Abdulsattar Qureshi, Umesh Vishnu Chaudhari, Raj Gopal Venkat, V.S.N. Murty Kadiyala, Sairam VVM Kalapatapu, Vaibhav Jain, Trinadha Rao Chitturi
-
Publication number: 20210053947Abstract: The present invention provides novel heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/degraders and process for their preparation.Type: ApplicationFiled: October 28, 2020Publication date: February 25, 2021Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITEDInventors: Rajan Kumar PAL, Amit Pravinbhai SEDANI, Kaushikkumar Dhanjibhai PRAJAPATI, Dijixa Pinakin RANA, Sandeep Pankajbhai PATHAK, Japan Nitinkumar DESAI, Jayraj Dilipbhai ARADHYE, Bhavesh Mohanbhai PANCHAL, Indraneel GHOSH, Trinadha Rao CHITTURI
-
Publication number: 20210024504Abstract: A selective estrogen receptor degrader (SERD), a compound 3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, and its S enantiomer, (2S)-3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol, or pharmaceutically acceptable salts thereof. Also provided are processes for their preparation. Also provided for is the use of these compounds for the treatment of diseases which are related to modulation of estrogen receptors, such as ER-positive breast cancer.Type: ApplicationFiled: July 22, 2020Publication date: January 28, 2021Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITEDInventors: Rajan Kumar PAL, Biswajit SAMANTA, Jayraj Dilipbhai ARADHYE, Sandeep Pankajkumar PATHAK, Kaushik Dhanjibhai PRAJAPATI, Bhavesh Mohanbhai PANCHAL, Trinadha Rao CHITTURI
-
Publication number: 20210015805Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 1, 2020Publication date: January 21, 2021Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Krishnaji DAMLE, Sanjay Nandlalji MANDHANE, Manoj Atmaramji UPADHYA, Sameer Vishwanath MEHETRE, Gajanan Uttamrao CHIDREWAR, Prabal SENGUPTA, Trinadha Rao CHITTURI
-
Patent number: 10865199Abstract: The present invention provides novel heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/degraders and process for their preparation.Type: GrantFiled: October 26, 2016Date of Patent: December 15, 2020Assignee: Sun Pharma Advanced Research Company LimitedInventors: Ranjan Kumar Pal, Amit Pravinbhai Sedani, Kaushikkumar Dhanjibhai Prajapati, Dijixa Pinakin Rana, Sandeep Pankajbhai Pathak, Japan Nitinkumar Desai, Jayraj Dilipbhai Aradhye, Bhavesh Mohanbhai Panchal, Indraneel Ghosh, Trinadha Rao Chitturi
-
Patent number: 10849887Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3, alkyl, C1-3, haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 2, 2017Date of Patent: December 1, 2020Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Krishnaji Damle, Sanjay Nandlalji Mandhane, Manoj Atmaramji Upadhya, Sameer Vishwanath Mehetre, Gajanan Uttamrao Chidrewar, Prabal Sengupta, Trinadha Rao Chitturi
-
Publication number: 20190275017Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3, alkyl, C1-3, haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 2, 2017Publication date: September 12, 2019Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Krishnaji DAMLE, Sanjay Nandlalji MANDHANE, Manoj Atmaramji UPADHYA, Sameer Vishwanath MEHETRE, Gajanan Uttamrao CHIDREWAR, Prabal SENGUPTA, Trinadha Rao CHITTURI
-
Patent number: 10179800Abstract: The present invention relates to crystalline forms of S-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl] 6?,9?-difluoro-17?-(furan-2-yl)carbonyloxy-11?-hydroxy-16?-methyl-3-oxoandrosta-1,4-diene-17?-carbothioate, an anti-inflammatory and anti-allergic glucocorticoid compound.Type: GrantFiled: January 30, 2016Date of Patent: January 15, 2019Assignee: Sun Pharma Advanced Research Company LimitedInventors: Jiten Ranchhodbhai Patel, Gopalkumar Chimanlal Patel, Gaurav Sanjivkumar Sheth, Trinadha Rao Chitturi
-
Publication number: 20180354936Abstract: The present invention provides novel heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/degraders and process for their preparation.Type: ApplicationFiled: October 26, 2016Publication date: December 13, 2018Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITEDInventors: Ranjan Kumar PAL, Amit Pravinbhai SEDANI, Kaushikkumar Dhanjibhai PRAJAPATI, Dijixa Pinakin RANA, Sandeep Pankajbhai PATHAK, Japan Nitinkumar DESAI, Jayraj Dilipbhai ARADHYE, Bhavesh Mohanbhai PANCHAL, Indraneel GHOSH, Trinadha Rao CHITTURI
-
Patent number: 9024021Abstract: The present invention relates to novel diarylacetylene hydrazide compounds of formula (I) or pharmaceutically acceptable salt thereof, as tyrosine kinase inhibitors, the process for their preparation, and to the use of the compounds of formula (I) in the preparation of pharmaceutical compositions for the therapeutic treatment of disorders related to tyrosine kinases, in warm-blooded animals.Type: GrantFiled: January 23, 2012Date of Patent: May 5, 2015Assignee: Sun Pharma Advanced Research Company Ltd.Inventors: Prabal Sengupta, Hemant Ashvinbhai Chokshi, Chetan Surjitsingh Puri, Sabbirhusen Yusufbhai Chimanwala, Varun Anilkumar Mehta, Dipali Manubhai Desai, Trinadha Rao Chitturi, Rajamannar Thennati